The short version of nuclear receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-06 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
== In nature == Taurine is widely distributed and abundant in nature, particularly in animal tissues. and further, as substrates in the biosynthesis of bile salts. Taurine concentrations in human cells may derive from at least three processes:
Transport phenomena Aerodynamics Applied mechanics Bernoulli's principle Communicating vessels Computational fluid dynamics Compressor map Secondary flow Different types of boundary conditions in fluid dynamics Fluid–structure interaction Immersed boundary method Stochastic Eulerian Lagrangian method Stokesian dynamics Smoothed-particle hydrodynamics
Thymosin beta-4 is considered a performance-enhancing substance and is banned in sports by the World Anti-Doping Agency due to its effect of aiding soft tissue recovery and enabling higher training loads. It was central to two controversies in Australia in the 2010s which saw a large proportion of the playing lists from two professional football clubs – the Cronulla-Sutherland Sharks of the National Rugby League and the Essendon Football Club of the Australian Football League – found guilty of doping and suspended from playing; in both cases, the players were administered thymosin beta-4 in a program organised by sports scientist Stephen Dank.
Sources: en.wikipedia.org
=== Food === One scene in Tanizaki's novel takes place between the protagonist's father-in-law and his young mistress O-hisa, described as "doll-like". (O-hisa herself is a symbol of the Kansai Japanese culture of Kyoto.) His daughter, Misako, and her husband have come to his home to discuss their divorce. He asks O-hisa to look after Kaname in his home while he takes his daughter, Misako, to a restaurant. The restaurant, Hyotei, is a traditional Japanese-style restaurant (和食処, washokudokoro) in the well-to-do Nanzen-ji neighborhood of Kyoto where the eponymous Zen Temple is located. When questioned about the food available to serve Kaname, O-hisa replies she has "only" salmon roe, baked trout and salad. When his father-in-law makes some disparaging remarks about the humble offerings, Kaname compares O-hisa's cooking favorably to the restaurant Hyotei where the "old man" will be dining with his daughter. "I'll have a feast" Kaname concludes. It is clear that O-hisa is simply being modest in her description of the food, comparing it humbly to the upscale dining at Hyotei. Other scenes in the book detail how O-hisa was trained by Misako's father to prepare food catering to his preference for traditional Kyoto-style cuisine. Some of the particular nuances of Tanizaki's cultural references and imagery are obscure in the English translation.
==== Japan ==== In April 2021, Zipline announced a partnership with an investor, Toyota Tsusho, to deliver medical products in Japan. While most Zipline facilities are staffed by locally hired operators employed by Zipline, the facilities in Japan are distinct in that they are operated by Sora-iina, a Toyota Tsusho Group company, and staffed by Toyota Tsusho employees. Zipline provides hardware and training in an OEM capacity. Construction of the first distribution center was completed in April 2022 on Fukue Island in the Gotō Islands. The drone delivery service will supply medical and pharmaceutical products to medical institutions and pharmacies in the Gotō Islands, which include 140 total islands (and five main localities). The use of drone delivery to assure routine distribution of medical products is expected to cut current sea and air transport options from several hours down to 30 minutes.
=== Mixing solutions === Often mixing hydroponic solutions using individual salts is impractical for hobbyists or small-scale commercial growers because commercial products are available at reasonable prices. However, even when buying commercial products, multi-component fertilizers are popular. Often these products are bought as three part formulas which emphasize certain nutritional roles. For example, solutions for vegetative growth (i.e. high in nitrogen), flowering (i.e. high in potassium and phosphorus), and micronutrient solutions (i.e. with trace minerals) are popular. The timing and application of these multi-part fertilizers should coincide with a plant's growth stage. For example, at the end of an annual plant's life cycle, a plant should be restricted from high nitrogen fertilizers. In most plants, nitrogen restriction inhibits vegetative growth and helps induce flowering.
Leading up to the passing of the laws, there was fierce opposition to them, above all by the FDP, the rising German student movement, a group calling itself Notstand der Demokratie ("Democracy in a State of Emergency") and the labour unions. Demonstrations and protests grew in number, and in 1967 the student Benno Ohnesorg was shot in the head by a policeman. The press, especially the tabloid Bild-Zeitung newspaper, launched a campaign against the protesters. By 1968, a stronger desire to confront the Nazi past had come into being. In the 1970s environmentalism and anti-nationalism became fundamental values among left-wing Germans. As a result, in 1979 the Greens were able to reach the 5% minimum required to obtain parliamentary seats in the Free Hanseatic City of Bremen state election, and with the foundation of the national party in 1980 developed into one of the most politically successful green movements in the world. Another result of the unrest in the 1960s was the founding of the Red Army Faction (RAF). The RAF was active from 1968, carrying out a succession of terrorist attacks in West Germany during the 1970s. Even in the 1990s, attacks were still being committed under the name RAF. The last action took place in 1993, and in 1998 the group announced it was ceasing activities.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.